Levitra

Patients should tell their doctor if they have nausea, vomiting, or abdominal pain, which may be signs of pancreatitis, or if they have or have had liver disease such as hepatitis B or C.

In patients taking protease inhibitors, increased bleeding (in patients with hemophilia) and diabetes/high blood sugar have occurred.Changes in body fat have been seen in some patients receiving anti- retroviral therapy.

The cause and long-term health effects of these conditions are not known at this time.

Some patients receiving lopinavir/ritonavir have had large increases in triglycerides and cholesterol.

Varying degrees of cross-resistance among protease inhibitors have been observed.The most commonly reported side effects of moderate severity are: abdominal pain, abnormal bowel movements, diarrhea, feeling weak or tired, headache, and nausea.

Children taking lopinavir/ritonavir may sometimes get a skin rash.

This is not a complete list of reported side effects.Diarrhea may be more common in patients taking lopinavir/ritonavir capsules once-daily compared to the twice-daily dose (57 percent...

If SLE-like symptoms occur, discontinuation of BiDil should be considered.

Residua have been detected many years after discontinuation of hydralazine.

Symptomatic hypotension may occur with even small doses of BiDil.

BiDil should be used with caution in volume depleted or hypotensive patients.

Hydralazine can cause tachycardia potentially leading to myocardial ischemia and anginal attacks.

Careful clinical and hemodynamic monitoring is recommended when BiDil is administered to patients with acute myocardial infarction to avoid hypotension and tachycardia.

Isosorbide dinitrate therapy may aggravate angina associated with hypertrophic cardiomyopathy.

Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness and tingling, which may be related to an antipyridoxine effect.

Caution should be exercised if BiDil is used with MAO inhibitors, alcohol, sildenafil, vardenafil or tadalafil.

Headache (50 percent) and dizziness (32 percent) were the two most frequent adverse events and were more than twice as frequent in the BiDil group.

Viagra is a registered trademark and Revatio is a trademark of Pfizer, Inc.;